Will payers support Amgen’s ‘bolus’ of eager Aimovig patients in time to fend off migraine rivals?
admin 27th July 2018 Uncategorised 0Even though Amgen and Novartis rolled out their hot new migraine drug, Aimovig, at a lower-than-expected price of $6,900, analysts are worried that payer pushback will negatively affect the market potential of the drug. Amgen’s top execs did little to appease those fears during the company’s second-quarter earnings call.
More: Will payers support Amgen’s ‘bolus’ of eager Aimovig patients in time to fend off migraine rivals?
Source: fierce